OralDosed ingredientTherapeutic flag
Cosmetic cross-reference
Gemfibrozil
CAS 25812-30-0
Gemfibrozil (CAS 25812-30-0) is a Phase 4 pharmaceutical compound with 8 bioactivity targets and 442 adverse event associations.
SOURCE
NLM DailyMed
Label records
1
SOURCE
EMBL-EBI ChEMBL
Bioactivity
15
SOURCE
DrugCentral / FAERS
Adverse signals
442
SOURCE
IUPHAR / PharmGKB
PubMed IDs
2
SOURCE
ChEMBL 36
B25820EEF0F0
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Gemfibrozil
CAS Number
25812-30-0
UNII
Q8X02027X3
InChIKey
HEMJJKBWTPKOJG-UHFFFAOYSA-N
ChEMBL ID
CHEMBL457
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
Lopid
dosed ingredientnatural productoraltherapeutic flag
SOURCE
ChEMBL 36
B25820EEF0F0
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL457 | Small molecule
SOURCE
Ingredients table / CosIng profile
same-CAS cross-reference
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
SOURCE
DailyMed SPL XML
1 label row
Drug Label Active Ingredients
Active ingredient and active moiety rows from source drug product labels.
| Product | Ingredient | Active Moiety | Effective |
|---|---|---|---|
| GEMFIBROZIL | GEMFIBROZIL Q8X02027X3 |
GEMFIBROZIL | 20260504 |
SOURCE
ChEMBL 36 activities + assays
15 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 21519.25476923077 nM | 130 | - |
| - | Potency | 33490.09090909091 nM | 21 | - |
| - | IC50 | 33891.443636363634 nM | 10 | - |
| - | EC50 | 76466.66666666667 nM | 9 | - |
| - | Ki | 4575.5 nM | 2 | - |
| - | IC50 | 0.1 ug.mL-1 | 1 | - |
| - | Kd | 100 nM | 1 | - |
| Lipoprotein lipase Enzyme |
- | - | - | Homo sapiens |
| Transthyretin Secreted |
Kd | 7 | - | Homo sapiens |
| Cytochrome P450 2C8 Enzyme |
Ki | 5.74 | - | Homo sapiens |
| Cytochrome P450 2C9 Enzyme |
Ki | 4.523 | - | Homo sapiens |
| Peroxisome proliferator-activated receptor alpha Nuclear hormone receptor |
EC50 | 4.23 | - | Homo sapiens |
| Peroxisome proliferator-activated receptor gamma Nuclear hormone receptor |
EC50 | 4.17 | - | Homo sapiens |
| Fatty acid-binding protein, liver Unclassified |
Ki | 5.73 | - | Rattus norvegicus |
| CDGSH iron-sulfur domain-containing protein 1 Unclassified |
Ki | 5.14 | - | Homo sapiens |
SOURCE
DrugCentral 2023 / FAERS disproportionality
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Rhabdomyolysis | 515 | 973.391 | 10039020 |
| Blood creatine phosphokinase increased | 164 | 198.461 | 10005470 |
| Blood triglycerides increased | 110 | 195.277 | 10005839 |
| Acute kidney injury | 449 | 176.934 | 10069339 |
| Coronary artery disease | 145 | 153.947 | 10011078 |
| Myalgia | 238 | 137.917 | 10028411 |
| Myocardial infarction | 226 | 133.052 | 10028596 |
| Drug interaction | 331 | 112.734 | 10013710 |
| Off label use | 113 | 102.997 | 10053762 |
| Cardiac failure congestive | 174 | 102.27 | 10007559 |
| Drug hypersensitivity | 294 | 101.749 | 10013700 |
| Pancreatitis | 111 | 81.851 | 10033645 |
| Drug ineffective | 205 | 73.901 | 10013709 |
| Myopathy | 54 | 67.819 | 10028641 |
| Drug intolerance | 16 | 62.002 | 10061822 |
| Blood glucose increased | 125 | 56.484 | 10005557 |
| Treatment failure | 5 | 55.897 | 10066901 |
| International normalised ratio increased | 93 | 53.009 | 10022595 |
| Chronic kidney disease | 102 | 52.079 | 10064848 |
| Polymyositis | 23 | 50.945 | 10036102 |
| Synovitis | 3 | 47.788 | 10042868 |
| Hyperglycaemia | 83 | 47.197 | 10020635 |
| Renal failure | 159 | 42.02 | 10038435 |
| Joint swelling | 31 | 41.308 | 10023232 |
| Granulocytopenia | 31 | 41.132 | 10018687 |
| Chromaturia | 46 | 39.889 | 10008796 |
| Product use issue | 19 | 38.56 | 10076309 |
| Infusion related reaction | 23 | 37.43 | 10051792 |
| Blood creatinine increased | 123 | 37.155 | 10005483 |
| Myositis | 37 | 36.978 | 10028653 |
| Lip infection | 10 | 36.624 | 10065755 |
| Angioedema | 76 | 36.526 | 10002424 |
| Hypoglycaemia | 90 | 36.34 | 10020993 |
| Pancreatitis acute | 59 | 36.206 | 10033647 |
| Maternal exposure during pregnancy | 11 | 35.473 | 10071408 |
| Haemodialysis | 34 | 35.204 | 10018875 |
| Hypertriglyceridaemia | 31 | 34.798 | 10020869 |
| Acute interstitial pneumonitis | 13 | 34.024 | 10066728 |
| Intentional product use issue | 11 | 33.116 | 10076308 |
| Wound | 7 | 32.328 | 10052428 |
| Glossodynia | 8 | 32.294 | 10018388 |
| Hyperlipidaemia | 42 | 30.995 | 10062060 |
| Blood glucose decreased | 42 | 30.889 | 10005555 |
| Cerebrovascular accident | 118 | 30.022 | 10008190 |
| High density lipoprotein decreased | 19 | 29.576 | 10020060 |
| Diabetes mellitus | 78 | 28.971 | 10012601 |
| General physical health deterioration | 29 | 28.647 | 10049438 |
| Arthropathy | 22 | 27.893 | 10003285 |
| Hyperkalaemia | 85 | 27.01 | 10020646 |
| Renal cyst | 30 | 26.627 | 10038423 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR ligand-target interactions
4 interactions
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| Peroxisome proliferator-activated receptor-α PPARA |
Agonist | 4.230000019073486 pEC50 | 21889235 |
| OATP1B1 SLCO1B1 |
Inhibition | - | 17470528 |
| OATP1B3 SLCO1B3 |
Inhibition | - | - |
| OATP2B1 SLCO2B1 |
Inhibition | - | - |
SOURCE
RxNorm drug names
4 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| Gemfibrozil | 4719 | SU | MTHSPL |
| GEMFIBROZIL | 4719 | SU | MTHSPL |
| gemfibrozil | 4719 | IN | RXNORM |
| Lopid | 202999 | BN | RXNORM |
SOURCE
SIDER side-effect resource
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abdominal pain | gemfibrozil | LLT | C0000737 |
| Abdominal pain | gemfibrozil | PT | C0000737 |
| Abdominal pain upper | gemfibrozil | PT | C0232492 |
| Acute appendicitis | gemfibrozil | LLT | C0085693 |
| Alopecia | gemfibrozil | LLT | C0002170 |
| Alopecia | gemfibrozil | PT | C0002170 |
| Anaemia | gemfibrozil | LLT | C0002871 |
| Anaemia | gemfibrozil | PT | C0002871 |
| Anaphylactic shock | gemfibrozil | LLT | C0002792 |
| Anaphylactic shock | gemfibrozil | PT | C0002792 |
| Angioedema | gemfibrozil | LLT | C0002994 |
| Angioedema | gemfibrozil | PT | C0002994 |
| Angioedema of larynx | gemfibrozil | LLT | C0857323 |
| Antinuclear antibody increased | gemfibrozil | LLT | C1610056 |
| Antinuclear antibody increased | gemfibrozil | PT | C1610056 |
| Antinuclear antibody positive | gemfibrozil | LLT | C0151480 |
| Antinuclear antibody positive | gemfibrozil | PT | C0151480 |
| Appendicitis | gemfibrozil | LLT | C0003615 |
| Appendicitis | gemfibrozil | PT | C0003615 |
| Appendicitis | gemfibrozil | PT | C0003615 |
| Arthralgia | gemfibrozil | LLT | C0003862 |
| Arthralgia | gemfibrozil | PT | C0003862 |
| Asthenia | gemfibrozil | PT | C0004093 |
| Atrial fibrillation | gemfibrozil | LLT | C0004238 |
| Atrial fibrillation | gemfibrozil | PT | C0004238 |
| Bacterial infection | gemfibrozil | LLT | C0004623 |
| Bacterial infection | gemfibrozil | PT | C0004623 |
| Blood alkaline phosphatase increased | gemfibrozil | PT | C0852911 |
| Blood and lymphatic system disorders | gemfibrozil | - | C0851353 |
| Blood bilirubin increased | gemfibrozil | LLT | C0311468 |
| Blood bilirubin increased | gemfibrozil | PT | C0311468 |
| Blood creatine phosphokinase increased | gemfibrozil | PT | C0853034 |
| Bone marrow depression | gemfibrozil | LLT | C0151773 |
| Breast disorder | gemfibrozil | LLT | C0006145 |
| Breast disorder | gemfibrozil | PT | C0006145 |
| Cataract | gemfibrozil | LLT | C0086543 |
| Cataract | gemfibrozil | PT | C0086543 |
| Cerebral haemorrhage | gemfibrozil | LLT | C2937358 |
| Cerebral haemorrhage | gemfibrozil | PT | C2937358 |
| Chest pain | gemfibrozil | LLT | C0008031 |
| Chest pain | gemfibrozil | PT | C0008031 |
| Cholecystitis | gemfibrozil | LLT | C0008325 |
| Cholecystitis | gemfibrozil | PT | C0008325 |
| Cholelithiasis | gemfibrozil | LLT | C0008350 |
| Cholelithiasis | gemfibrozil | PT | C0008350 |
| Colitis | gemfibrozil | LLT | C0009319 |
| Colitis | gemfibrozil | PT | C0009319 |
| Common cold | gemfibrozil | LLT | C0009443 |
| Confusional state | gemfibrozil | LLT | C0009676 |
| Confusional state | gemfibrozil | PT | C0009676 |
| Connective tissue disorder | gemfibrozil | LLT | C0009782 |
| Connective tissue disorder | gemfibrozil | PT | C0009782 |
| Constipation | gemfibrozil | LLT | C0009806 |
| Constipation | gemfibrozil | PT | C0009806 |
| Convulsion | gemfibrozil | LLT | C0036572 |
| Convulsion | gemfibrozil | PT | C0036572 |
| Cough | gemfibrozil | LLT | C0010200 |
| Cough | gemfibrozil | PT | C0010200 |
| Creatine phosphokinase increased | gemfibrozil | LLT | C0151576 |
| Depression | gemfibrozil | LLT | C0011570 |
| Depression | gemfibrozil | PT | C0011570 |
| Dermatitis | gemfibrozil | LLT | C0011603 |
| Dermatitis | gemfibrozil | PT | C0011603 |
| Dermatitis | gemfibrozil | PT | C0011603 |
| Dermatitis exfoliative | gemfibrozil | LLT | C0011606 |
| Dermatitis exfoliative | gemfibrozil | PT | C0011606 |
| Diarrhoea | gemfibrozil | LLT | C0011991 |
| Diarrhoea | gemfibrozil | PT | C0011991 |
| Disturbance in sexual arousal | gemfibrozil | PT | C0855242 |
| Dizziness | gemfibrozil | LLT | C0012833 |
| Dizziness | gemfibrozil | PT | C0012833 |
| Dizziness | gemfibrozil | PT | C0012833 |
| Drug interaction | gemfibrozil | LLT | C0687133 |
| Drug interaction | gemfibrozil | PT | C0687133 |
| Dysgeusia | gemfibrozil | LLT | C0013378 |
| Dysgeusia | gemfibrozil | PT | C0013378 |
| Dyspepsia | gemfibrozil | LLT | C0013395 |
| Dyspepsia | gemfibrozil | PT | C0013395 |
| Eczema | gemfibrozil | LLT | C0013595 |
| Eczema | gemfibrozil | PT | C0013595 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Gemfibrozil used for in pharmaceutical contexts?
Gemfibrozil (CAS 25812-30-0) appears in DailyMed active-ingredient label rows, including GEMFIBROZIL.
What are the known adverse events for Gemfibrozil?
Gemfibrozil has 442 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Rhabdomyolysis, Blood creatine phosphokinase increased, Blood triglycerides increased, Acute kidney injury, Coronary artery disease. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Gemfibrozil also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Gemfibrozil with EU status "prohibited".
What clinical phase is Gemfibrozil in?
Gemfibrozil is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Gemfibrozil?
Gemfibrozil has 15 bioactivity rows in this page query. Rendered target entries include Lipoprotein lipase, Transthyretin, Cytochrome P450 2C8, Cytochrome P450 2C9, Peroxisome proliferator-activated receptor alpha.